New supramolecular alzheimers drugs

New supramolecular alzheimers drugs – Supramolecular chemistry could provide a new avenue in the treatment of Alzheimer’s disease, say scientists in China. The group demonstrates for the first time that supramolecular complexes can inhibit the aggregation of a peptide thought to cause Alzheimer’s disease. Reference: H Yu et al, Chem. Sci., 2012, DOI: 10.1039/c2sc20372c

New supramolecular alzheimers drugs – Supramolecular chemistry could provide a new avenue in the treatment of Alzheimer’s disease, say scientists in China. The group demonstrates for the first time that supramolecular complexes can inhibit the aggregation of a peptide thought to cause Alzheimer’s disease.

(10.1039/c2sc20372c)

Just to clarify: we don’t actually know what causes Alzheimer’s disease nor whether amyloid plaques are a cause or an effect. New drugs that focus on this etiology may not necessarily succeed, although if they do they would add to the evidence for plaques being a cause.

http://en.wikipedia.org/wiki/Alzheimers#Cause

Bibliography

Author: Robert Slinn

Robert Slinn is ChemSpy's guest columnist. You can read his chemical news updates under the banner "Slinn Pickings". Robert is a Chartered Chemist (CChem), Member of the Royal Society of Chemistry (MRSC) and is a Visiting Researcher in the Department of Chemistry at the University of Liverpool. He has extensive experience in R&D: synthesis, analysis and analytical methods development; troubleshooting, consultancy, and teaching/training methods in industry and in academia. Robert is also 'Physical Methods' author for the Specialist Periodical Report series 'Organophosphorus Chemistry', published by Royal Society of Chemistry, Cambridge, UK. Robert has worked alongside David on the Bedside Book of Chemistry and a major Thomson-Reuters report on the state of the pharmaceutical industry for the 2011 International Year of Chemistry